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Despite a growing body of research over the last few decades, mental disorders,
including anxiety disorders or depression, are still one of the most prevalent and hardest
to treat health burdens worldwide. Since pharmacological treatment with a single drug
is often rather ineffective, approaches such as co-medication with functionally diverse
antidepressants (ADs) have been discussed and tried more recently. Besides classical
ADs, there is a growing number of candidate targets identified as potential starting points
for new treatment methods. One of these candidates, the FK506 binding protein 51
(FKBP51) is linked to a number of psychiatric disorders in humans. In this study, we
used SAFit2—a newly developed modulator of FKBP51, which has shown promising
results in rodent models for stress-related disorders delivered in a depot formulation. We
combined SAFit2 with the commonly prescribed selective serotonin reuptake inhibitor
(SSRI) escitalopram and performed basic behavioral characterization in a mouse model.
Remarkably, co-application of SAFit2 lowered the efficacy of escitalopram in anxiety-
related tests but improved stress coping behavior. Given the fact that mental diseases
such as anxiety disorders or depression can be divided into different sub-categories,
some of which more or less prone to stress, SAFit2 could indeed be a highly beneficial
co-medication in very specific cases. This study could be a first, promising step towards
the use of FKBP51 modulators as potent and specific enhancers of AD efficiency for
subclasses of patients in the future.
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INTRODUCTION
In recent years, our understanding and perception of mental disorders, like anxiety disorders
or depression, as a major burden for our society, has increased tremendously. It is well known
that some of these illnesses are highly prevalent and account for immense costs to health
care systems all over the world (Ferrari et al., 2013). To make matters worse, the efficiency of
available treatments, especially pharmacological interventions, is often very low and individual
response to a specific treatment regimen is unpredictable (Hirschfeld, 1999). Additionally,
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most of the available pharmacological treatments are based
on the same principle, namely modulating the levels of
neurotransmitters in the brain.
The majority of the widely prescribed antidepressants
(ADs), like paroxetine or escitalopram, alter the availability of
monoamines like serotonin in the synaptic cleft. Although these
so-called selective serotonin reuptake inhibitors (SSRIs) prove
to be effective in patients with anxiety disorders as well as
major depression, the effect size is modest and there is a high
non-responder rate (Jakobsen et al., 2017). The late onset and
high relapse rates of these drugs are additive drawbacks, making
therapy a tedious trial and error process (Rush et al., 2006).
The lack of a mechanistically broader drug spectrum makes it
hard to treat non-responsive patients, and so-called ‘‘treatment-
resistant’’ patients often lack a real chance of recovery. For this
reason, focus has shifted towards a broad cluster of cellular
mechanisms and pathways linked to mental disorders as well
as approaches that combine different methods and treatments
to achieve more reliable results. General anxiety disorder, for
example, is often treated with common SSRIs alone; however,
AD response can be enhanced by psychotherapy (Strawn et al.,
2018).
One of the main pathways of interest in relation to major
depression is the hypothalamic-pituitary-adrenal (HPA) axis,
which is a key player in many stress-related disorders. Its
regulation is known to be crucial for mental health (de Kloet
et al., 2005) and many promising targets for the treatment of
mental diseases are mediators of HPA axis regulation (Ben-
Efraim et al., 2011; Kang et al., 2018; Stonawski et al., 2018).
Two of the key regulatory components of the HPA axis are
the high affinity mineralocorticoid receptor (MR) and the
lower affinity glucocorticoid receptor (GR), which mediate
the glucocorticoid negative feedback of the HPA axis and
therefore an appropriate termination of the stress response
(Ulrich-Lai and Herman, 2009). Altered glucocorticoid signaling
and thus impaired HPA-axis activity has been observed in
many patients with mood and anxiety disorders (Pariante and
Miller, 2001). Both MR and GR are present in the cell as
part of a larger protein complex, which includes HSP90 and
a number of regulatory proteins. One of these proteins
is the co-chaperone FK506 binding protein 51 (FKBP51),
which reduces binding sensitivity of the GR to its ligand
(Pratt et al., 2006; Criado-Marrero et al., 2018). Interestingly,
polymorphisms in the regulatory regions of the gene encoding
FKBP51 (called fkbp5) are associated with depression and
post-traumatic stress disorder in humans (Binder et al., 2004,
2008).
FKBP51 has become one of the top candidates for novel
interventions and treatments for stress-related disorders and
as a result there is a rapidly growing body of preclinical
data on FKBP51. Indeed, Scharf et al. (2011) showed that
FKBP51 is regulated in a stress-dependent manner in several
brain regions, including the hippocampus, the paraventricular
nucleus (PVN) of the hypothalamus and the amygdala.
Conventional FKBP51 knockout (KO) mice are less affected
by chronic social defeat stress (Hartmann et al., 2012) and
FKBP51 signaling in the amygdala is crucially involved in
anxiety-related behavior in mice (Hartmann et al., 2015). SAFit2,
the first potent, brain permeable and highly specific inhibitor
of FKBP51 was recently developed and was shown to increase
neuroendocrine feedback and reduce anxiety inmice (Gaali et al.,
2015).
For further development of FKBP51 antagonists as potential
ADs and anxiolytics, it is important to understand whether
pharmacological FKBP51 inhibition interferes with the action
of commonly prescribed ADs, which are also often prescribed
for anxiety disorders. Although combining ADs increases the
risk of an uncontrolled aggravation of negative side effects,
co-medication can improve symptoms in some patients (Thase,
2006). As FKBP51 KO mice are less responsive to the acute
effects of an SSRI treatment (Gassen et al., 2014), it is
important to assess whether the pharmacological inhibition of
FKBP51 might alter the efficacy of SSRI treatment. Therefore,
in this study, we investigated the effects of escitalopram with
or without FKBP51 inhibition on anxiety and stress coping
behavior.
MATERIALS AND METHODS
Animals
Animals used for this experiment were 12-week-old male mice,
bred on a C57BL/6N background in our in-house facilities.
Testing was carried out in the animal facilities of the Max-
Planck-Institute of Psychiatry (Munich, Germany). To ensure
sufficient acclimation, the animals were single housed andmoved
from our holding rooms to the test room 2 weeks prior to
the experiment. All animals were housed in standard cages
(21 cm × 15 cm × 14 cm, Plexiglas) and conditions were
kept constant during the whole experiment (light-dark-cycle
12 h:12 h, lights on at 08:00 am, 23 ± 2◦C, humidity 55%). The
animals had ad libitum access to food (Altromin 1324, Altromin
GmbH, Germany) and tap water.
The experiment was carried out in accordance with the
European Communities Council Directive 2010/63/EU. All
animal suffering wasminimized during the testing. The protocols
were approved by the committee for the Care and Use of
Laboratory Animals of the Government of Upper Bavaria,
Germany.
Experimental Design
We used a 2 × 2 design with four experimental groups:
(1) control animals, injected with empty vesicular phospholipid
gel (VPG) and vehicle; (2) SAFit2 animals injected with
SAFit2 VPG and vehicle; (3) escitalopram animals, injected
with empty VPG and escitalopram; and (4) SAFit2+escitalopram
animals, receiving both drugs. The initial group size was
n = 10 for each group. On day 1 of the experiment (see
a graphical representation of the experimental design in
Figure 1), half of the animals received SAFit2 treatment,
and the other half received an injection of the empty VPG
(see details for ‘‘Pharmacological Treatment’’ section below).
On the subsequent days, half of each group received either
the SSRI escitalopram or vehicle 30 min before behavioral
testing. The following tests were performed, always with a
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FIGURE 1 | Experimental time course: order of pharmacological treatment and behavioral tests. Empty and SAFit2 loaded vesicular phospholipid gel (VPG) was
injected subcutaneously on day 1. Behavioral tests were carried out on days 2–5 with a single intraperitoneal vehicle or escitalopram injection 30 min prior to each
test.
24-h inter-trial interval: Open Field (OF), Elevated Plus Maze
(EPM), Dark-Light Box (DaLi) and Forced Swim Test (FST).
The animals were sacrificed 24 h after the last behavioral
test.
Pharmacological Treatment
SAFit2 was applied using a VPG as a carrier as described
previously (Balsevich et al., 2017;Maiarù et al., 2018) where it was
shown to result in stable plasma and brain SAFit2 concentrations
with a drug half-life of about 7 days. Briefly, 200 µl of the
VPG with or without SAFit2 (gel loading at 10 mg SAFit2 per
g gel) were injected subcutaneously on day 1 of the experiment.
Escitalopram was obtained from Santa Cruz Biotechnology as a
crystalline powder and dissolved in H2O to a final concentration
of 1 mg/ml. The drug was injected intraperitoneally 30 min prior
to testing on experimental days 2–5. The administered dose was
10 mg/kg body weight and the injection volume was corrected to
the animal’s bodyweight accordingly.
BEHAVIORAL TESTS
All behavioral tests were carried out between 08:30 am and
12:30 pm in the same room the animals were housed in. All
tests were analyzed by an experienced researcher utilizing the
automated video-tracking software AnyMaze (Anymaze 4.99,
Stoelting, Wood Dale, IL, USA). All animals underwent the same
testing battery in the same order of tests. To minimize possible
carryover effects of the different behavioral tests, the order of
tests was arranged from the least stressful to the most stressful
(McIlwain et al., 2001).
Open Field Test (OF)
The OF was performed on day 2 in order to measure locomotion
as well as anxiety behavior in the animals. Testing was conducted
under low light conditions (∼15 lux) in an empty arena
(50 cm× 50 cm× 50 cm)made of gray polyvinyl chloride (PVC).
At the beginning of the test, animals were placed in one of the
corners of the apparatus. The total test time was 15 min, divided
into three time bins of 5 min each. For this test, parameters of
interest were the distance traveled, time spent immobile, as well
as the time animals spent investigating the most exposed and
therefore aversive mid-section (10 cm × 10 cm) of the arena
(Hartmann et al., 2015).
Elevated Plus Maze (EPM)
The EPM was performed on day 3 of the experiment. The maze
consisted of two opposed open arms (30 cm × 5 cm × 0.5 cm)
and two opposed enclosed arms (30 cm × 5 cm × 15 cm)
made of gray PVC, which were connected by a central platform
(5 cm× 5 cm) shaping a plus sign. The arena was elevated 50 cm
above the floor. At the start of the test, animals were placed into
the center of the plus maze facing a closed arm and were allowed
to explore the maze for 5 min. The time spent in the respective
arms as well as the number of open arm entries was analyzed.
Animals that fell off the open arm of the apparatus during testing
were excluded from the analysis (Müller et al., 2003).
Dark-Light Box (DaLi)
The DaLi was performed on day 4 of the experiment and served
as another paradigm to measure anxiety-related behavior. The
arena consisted of a rectangular box that was split into two
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compartments. The compartments were connected by a 4 cm
long tunnel, allowing the animals to move freely between both
compartments. The lit compartment (30 cm × 20 cm × 25 cm)
was illuminated by an external light source (∼700 lux), creating
an aversive environment for the animals. The dark compartment
(15 cm× 20 cm× 25 cm) on the other hand was not illuminated
(∼5 lux). The time the animals spent in each chamber during the
5 min test duration was measured (Hartmann et al., 2015).
Forced Swim Test (FST)
The FST was conducted on the last day of the experiment, as
it is considered to be the most stressful of all the tests. For the
FST, we used 2-liter glass beakers that were filled up to 1.5 liter
with water at room temperature. Water depth was chosen in a
way that the mice were neither able to touch the bottom of the
container, nor climb out of it, therefore creating an inevitable
stressful situation for the animals. Test duration was 5 min
and the animals were dried with a towel afterwards to prevent
hypothermia. The scored parameter was the time spent in active
escape behavior (struggling; Gaali et al., 2015).
Corticosterone
Blood samples were taken by tail cut 30 min (stress response)
and 90 min (stress recovery) after the onset of the FST. Basal
blood samples were taken from trunk blood at sacrifice 24 h
after the FST. All samples were collected in 1.5 ml EDTA-coated
microcentrifuge tubes (Kabe Labortechnik, Germany). Blood
samples were kept on ice and later centrifuged at 8,000 rpm at
4◦C for 15 min. Plasma was transferred to new, labeled tubes
and stored at −20◦C until determination of corticosterone
by radioimmunoassay (MP Biomedicals Inc.; sensitivity
12.5 ng/ml).
Statistical Analysis
The data are shown as means ± SEM, analyzed by the
commercially available software GraphPad Prism 7.03. Students’
t-test was employed for comparison of two independent groups.
Two-factorial (FKBP51 antagonist and AD) ANOVA was
employed for all other parameters. A significance level of p< 0.05
for main effects and p < 0.1 for interaction effects was followed
by Tukey’s post hoc test, with a nominal level of p < 0.05
considered significant. All values outside a margin of two times
standard deviation were considered outliers and excluded from
the analysis. Investigators were blinded to the experimental
groups during the experiments and data analysis.
RESULTS
Open Field
The OF is classically used to examine locomotor activity and
anxiety-like behavior. For the total distance traveled (Figure 2A),
ANOVA revealed no main effect of SAFit2 treatment
(F(1,36) = 3.567, p < 0.1), but a main effect of escitalopram
(F(1,36) = 56.03, p < 0.001) as well as an interaction effect
(F(1,36) = 3.196, p < 0.1). Under vehicle treated conditions,
SAFit2 had no effect on overall locomotion. Escitalopram
treatment significantly increased locomotor activity in both
groups. However, the escitalopram effect was significantly
reduced in SAFit2 treated animals compared to empty VPG
treated controls (p < 0.05). When the data were split up in
three 5-min time bins (Figure 2B), it becomes clear that the
moderating effect of SAFit2 treatment on the escitalopram effect
is mainly evident in the 2nd (p < 0.05) and 3rd (p < 0.05)
time bin.
Regarding the time the animals spent in the inner zone of
the OF (Figure 2C), ANOVA revealed no main effect of SAFit2
(F(1,34) = 0.3393, p > 0.05), but a main effect of escitalopram
(F(1,34) = 7.862, p < 0.01) as well as a significant interaction
effect (F(1,34) = 4.402, p < 0.05). In animals without SAFit2,
escitalopram application resulted in a marked anxiolytic effect,
indicated by the increased time spent in the inner zone of the OF
(p< 0.05). This effect was absent in animals treated with SAFit2.
Elevated Plus Maze
To test for anxiety-related and explorative behavior we employed
the EPM. Here, ANOVA revealed that SAFit2 (F(1,33) = 7.26,
p < 0.05) and escitalopram (F(1,33) = 31.41, p < 0.001)
FIGURE 2 | Behavioral alterations in the open field (OF) test. (A) Escitalopram (Esc) administration induced an increase in distance traveled during the test, which
was significantly ameliorated by SAFit2 treatment. (B) When splitting the test in three time-bins of 5 min each, we found no differences between the Esc groups in
the first 5 min. However, in time bins 2 and 3, co-medication significantly decreased the distance traveled when compared to the Empty/Esc group. (C) The
exploration of the inner zone of the OF is considered a measure of anxiety. Esc significantly increased the inner zone time of the animals, and this effect was blocked
in SAFit2 treated mice. #Main Esc effect, $main SAFit2 effect, §Esc–SAFit2 interaction effect, ∗significant post hoc effect at p < 0.05.
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FIGURE 3 | Treatment with SAFit2 and escitalopram (Esc) affected behavior in two different anxiety tests. (A) Overall locomotion in the Elevated Plus Maze (EPM)
was increased by Esc treatment and this effect was ameliorated by SAFit2. Anxiety-like behavior in the EPM measured by open arm entries (B) and open arm time
(C) was decreased after Esc treatment. When combined with the FK506 binding protein 51 (FKBP51) inhibitor, this effect was reduced for open arm entries, but not
significantly for open arm time. (D) In the Dark-Light box (DaLi), we again observed a significant interaction effect when comparing all four groups. #Main Esc effect,
$main SAFit2 effect, §Esc–SAFit2 interaction effect, ∗significant post hoc effect at p < 0.05, tpost hoc trend at p < 0.1.
treatment resulted in significant main effects in distance traveled.
However, there was no interaction between the four treatment
groups (F(1,33) = 0.2775, p > 0.1). In vehicle-treated animals,
SAFit2 had no significant effect on locomotion (p > 0.05),
but in escitalopram treated mice SAFit2 significantly reduced
locomotor activity compared to empty gel treated mice (p< 0.05;
Figure 3A).
SAFit2 did not induce a significant main effect when looking
at anxiety-related parameters e.g., the number of entries into
the open arm (F(1,33) = 1.521, p > 0.05; Figure 3B) or the
time animals spent on the open arms (F(1,33) = 0.658, p > 0.05;
Figure 3C). As expected, animals treated with escitalopram
had a significant increase in open arm entries (F(1,33) = 39.45,
p< 0.001) and time spent (F(1,33) = 12.39, p< 0.001). Again, this
anxiolytic effect was moderately dampened when escitalopram
was combined with SAFit2, as depicted by a trend towards a
lower number of entries into the open arms (p< 0.1; Figure 3B).
Dark-Light Box
Neither SAFit2, nor escitalopram induced significant main
effects on explorative behavior in the DaLi (escitalopram:
F(1,33) = 0.1, p > 0.05; SAFit2: F(1,33) = 0.038, p > 0.05).
Nonetheless, we saw a significant interaction effect, using
Two-Way ANOVA (F(1,33) = 5.838, p < 0.05; Figure 3D).
In line with our former observations, SAFit2 co-medication
significantly reduced the anxiolytic effect of escitalopram
treatment (p< 0.05).
Forced Swim Test
The FST is a recognized test to evaluate stress coping behavior
in rodents, as it confronts them with an unescapable stressful
situation. ANOVA revealed significant main effects for SAFit2
(F(1,32) = 7.21, p < 0.05) and escitalopram (F(1,32) = 19.55,
p < 0.001), as well as an interaction effect (F(1,32) = 4.474,
p < 0.05), when looking at the time animals spent struggling
(Figures 4A,B). SAFit2 alone had no effect on struggling
behavior. As expected, escitalopram treatment significantly
increased time spent struggling in both groups. Interestingly,
SAFit2 treatment significantly enhanced this effect when
considering the full testing time (Figure 4A, p < 0.05). When
analyzing the progression of the struggling behavior over
time, repeated measures ANOVA revealed a significant time ∗
escitalopram ∗ SAFit2 effect (F(3,33) = 2.947, p < 0.001). Post hoc
analysis showed that SAFit2 pretreatment significantly enhanced
escitalopram-induced struggling behavior especially in the last
4 min of the FST (p< 0.01).
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 November 2018 | Volume 12 | Article 262
Pöhlmann et al. FKBP51 Inhibition Alters Antidepressant Efficacy
FIGURE 4 | SAFit2 and escitalopram (Esc) treatment strongly affect behavior in the Forced Swim Test (FST). (A) Percentage of time the animals spent struggling in
the FST was significantly increased by both SAFit2, as well as Esc treatment. When both drugs were combined, animals spent more than 50% of the time actively
trying to escape the water. (B) When looking at the time course of the 5-min experiment, it becomes apparent that animals with a SAFit2 pre-treatment struggled
significantly more in the last 3 min of the FST. #Main Esc effect, $main SAFit2 effect, §Esc–SAFit2 interaction effect, ∗significant post hoc effect at p < 0.05.
Corticosterone
Corticosterone was measured at baseline and following an acute
stressor (forced swim) to determine HPA axis responsivity
and feedback. Under basal conditions, there were no main
(escitalopram: F(1,33) = 0.33, p > 0.05, SAFit2: F(1,33) = 1.82,
p > 0.05) or interaction (F(1,33) = 0.98, p > 0.05) effects
(Figure 5A). Following an acute stressor, ANOVA revealed no
main effects (escitalopram: F(1,33) = 2.434, p > 0.05, SAFit2:
F(1,33) = 1.389, p > 0.05), but a significant interaction effect
(F(1,33) = 3.239, p < 0.1; Figure 5B). SAFit2 pretreatment
significantly reduced the corticosterone response in vehicle
treated animals (p < 0.05), but not in escitalopram treated
animals (p > 0.05). At 90 min after the onset of the
stressor (recovery), we observed a significant SAFit2 effect
(F(1,33) = 5.481, p < 0.05), but no escitalopram (F(1,33) = 0.458,
p > 0.05) or interaction (F(1,33) = 0.002, p > 0.05) effect.
SAFit2 pretreatment lowered the corticosterone recovery levels,
an effect that was stronger in escitalopram-treated animals
(p < 0.05), while it did not reach post hoc significance in vehicle
treated animals (p> 0.05; Figure 5C).
DISCUSSION
In terms of pharmacological intervention, SSRIs are a physician’s
main weapon against mental illnesses like anxiety disorders
or major depressive disorder. However, their efficacy is
mediocre at best and we are in urgent need of alternatives.
In this study, we further investigated the potential use of
the FKBP51 inhibiting substance SAFit2, which targets a
different molecular mechanism. While SSRIs directly impact
the amount of available neurotransmitters in the synaptic cleft,
SAFit2 regulates the termination of the body’s stress response,
which is often dysfunctional across mental illnesses. In addition,
FKBP51 has been shown to regulate several protein-protein
interactions important for cellular function, which may be
affected by SAFit2 treatment (Gassen et al., 2015; Balsevich et al.,
2017). Here, we combined these two treatment approaches in
hope of obtaining a broader spectrum of beneficial properties
that may help more patients.
Our results suggest a very relevant interaction between
escitalopram and SAFit2. When applied exclusively, SAFit2 had
FIGURE 5 | Effects on hypothalamic-pituitary-adrenal (HPA) axis function. (A) Basal corticosterone secretion is not affected by SAFit2 or escitalopram (Esc)
treatment. (B) Thirty minutes following an acute stressor (response), SAFit2 reduces corticosterone secretion in vehicle treated animals, while no effect is observed
under Esc treatment. (C) Ninety minutes after the onset of the stressor (recovery), SAFit2 suppression of the HPA axis function is observed in both vehicle and
Esc-treated animals, but only reaches post hoc significance in the Esc-treated group. $Main SAFit2 effect, §Esc–SAFit2 interaction effect, ∗significant post hoc effect
at p < 0.05.
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very little impact on behavior. This might be due to the
relatively low dose used via the continuous release VPG
formulation. In addition, all tests were performed under
basal conditions. From earlier experiments we know that
SAFit2 induces (positive) behavioral effects on anxiety-related
behavior when used at higher doses or when combined with
a stressful challenge (Hartmann et al., 2015). In contrast,
escitalopram treatment resulted in robust behavioral alterations
in the animals, increasing their overall mobility and readiness
to assume risk and enhancing active stress coping behaviors.
For anxiety-related behavior, the addition of SAFit2 dampened
the anxiolytic effects of escitalopram, without canceling them
out completely. While an increase in neurotransmitter levels via
SSRI action reduces anxiety and fear, simultaneous disruption
of FKBP51 functionality seems to counteract this effect. This
finding is in line with the clinical observation that FKBP51 risk
allele carriers with high FKBP51 levels show an improved
response to SSRI treatment (Ellsworth et al., 2013). In addition,
FKBP51 KO mice were previously shown to respond less to SSRI
treatment (Gassen et al., 2014). In contrast to our observations in
the anxiety-related parameters, the addition of SAFit2 enhanced
the effects of AD application in the FST. In agreement with
former studies (Can et al., 2012), active stress coping in the FST
was significantly enhanced after escitalopram treatment, with the
effect being even larger in the presence of SAFit2.
The converse results in our experiments clearly demonstrate
how delicate and specific the outcome of co-medication can
be. In the current study a combination of serotonin reuptake
inhibition with FKBP51 blockade might be beneficial for the
treatment of symptoms that relate to stress coping, while positive
AD effects on anxiety-related parameters can be hampered by the
disruption of FKBP51 functionality. Onemight speculate that the
given challenge in each test is mediated by different pathways
or systems in the brain, which are ultimately differentially
affected by our combination of drugs. As we confirmed the
previously reported suppression of HPA axis reactivity following
SAFit2 treatment, it is possible that the behavioral effects of
SSRI treatment are modulated via the altered HPA axis function.
However, basal corticosterone levels were not different between
the groups. Furthermore, SSRIs have been shown to affect a
plethora of cellular pathways, some of which seem independent
of their function as SSRI (Einoch et al., 2017; Eskelund et al.,
2017). Similarly, the molecular functions of FKBP51 also largely
exceed its role as Hsp90/GR co-chaperone (Balsevich et al., 2017;
Fries et al., 2017; Hamilton et al., 2018). Indeed, SAFit2 likely
affects only some of the actions of FKBP51, while others may
not be modified. Thus, it is likely that with the development
of additional FKBP51-modulating drugs different aspects of
FKBP51 function can be targeted, which may enhance the
applicability of co-medication with SSRIs.
The current study also has a number of limitations.
Importantly the effects of SSRI treatment were only tested
following an acute treatment, while some SSRI-mediated effects
e.g., on anxiety-related behavior occur predominantly following
chronic treatment (Burghardt and Bauer, 2013). In addition,
only one class of ADs was tested. In the future, it will therefore
be important to test more combinations of various ADs with
SAFit2 following both acute and chronic treatment regiments.
Given the fact that we found positive effects on active stress
coping behavior in the FST, switching to an AD that affects the
dopamine or norepinephrine system could be a promising course
of action in future experiments (Bardal et al., 2011).
Overall, our results show the potential promise but also the
potential problems and limitations of co-medication when it
comes to the treatment of mental disorders. They also highlight
the importance and necessity of pre-clinical studies to determine
whether or not a chosen combination of drugs has the potential
to help patients. In conclusion, this study provides an important
characterization of the therapeutic capabilities of the newly
developed drug SAFit2 and its potential impact on classical
pharmacological treatments in the future.
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